Biocartis

Mechelen, Belgium Founded: 2007 • Age: 19 yrs Listed
Molecular assays for disease detection are developed using proprietary technology.

About Biocartis

Biocartis is a publicly listed company based in Mechelen (Belgium) founded in 2007. Molecular assays for disease detection are developed using proprietary technology. Biocartis has raised $305.3 million across 18 funding rounds from investors including Philips, Johnson & Johnson and KBC Bank & Verzekering. Biocartis has completed 1 acquisition, including Pronota. Its website biocartis.com draws about 11 thousand monthly visits. Biocartis offers products and services including Idylla Platform, Oncology Tests, and Research Assays. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Biocartis NV.

Company details

Biocartis was founded in 2007 in Mechelen, Belgium, within the molecular diagnostics sector. Proprietary micro-technology platforms are utilized for integrated molecular and immunodiagnostics. Multiplexed detection, quantification, and amplification of bio-analytes such as proteins, nucleic acids, and small molecules are enabled. Analysis of biomolecules linked to disease risk factors, early detection, staging, treatment selection, and monitoring is supported across various applications.

  • Headquarters Mechelen, Belgium
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website biocartis.com/en-US
  • Social LinkedIn X Facebook YouTube
  • Legal Name Biocartis Nv
Key Metrics
  • Total Equity Funding
    $305.3M (USD)

    in 18 rounds

  • Investors
    Philips

    & 18 more

  • Investments & Acquisitions

Products & Services of Biocartis

Biocartis offers a comprehensive portfolio of products and services, including Idylla Platform, Oncology Tests, and Research Assays.

Idylla Platform
Diagnostic Platform

Automated system for rapid molecular testing in oncology labs

Oncology Tests
Medical Assays

Tests for detecting mutations in cancer biomarkers quickly

Research Assays
Biomarker Tools

Assays for exploring new biomarkers in research settings

Apps and channels of Biocartis

its YouTube channel Biocartis has 211 subscribers and 21 videos.

Biocartis
YouTube 211 subscribers 21 videos Howto & Style
Open channel

Videos from Biocartis

The most watched videos on Biocartis's YouTube channel, Biocartis (211 subscribers). Click a video to play it here.

Idylla - powerfully simple
10.8K views
Meet Idylla™
10.8K views
How does Idylla work?
4.2K views
What is molecular diagnostics?
2.8K views

More on Biocartis.

Funding Insights of Biocartis

Biocartis has successfully raised a total of $305.3M across 18 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $305.3M
  • Total Rounds 18
  • First Round $14.9M

    (Oct 2009)

  • Investors Count 19

Latest 10 of 18 funding rounds of Biocartis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Sep 2022Post-IPO––
–
May 2021$1.7MGrant––
Dec 2020$181.8MPost-IPO––
–
Sep 2020$1.41MGrant––
Jan 2019$63.05MPost-IPO––
–
Jan 2018$225,081Grant––
Nov 2017$95.37MPost-IPO––
–
Nov 2016$35.02MPost-IPO––
–
Jul 2016$60.77MDebt – Conventional––
Mar 2016$272,409Grant––
Valuation history

19 investors in total: 19 institutional.

Investors in Biocartis

Biocartis has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Philips, Johnson & Johnson and KBC Bank & Verzekering.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Private equity is directed toward private and public companies.
sfpi-fpim.beBrussels, Belgium
Venture capital firm backed by Johnson & Johnson
jnjinnovation.com/jjdcCambridge, United States
Private debt funds are managed across multiple sectors.
2001pmv.euBrussels, Belgium
Sustainable investing in conscious consumer, energy transition, and healthy living sectors.
2011korys.be
Venture capital fund focused on multiple sectors
valiance-am.comLondon, United Kingdom
Healthcare investments are focused on life sciences ventures.
newrhein.comPhiladelphia, USA
Aescap is focused on investing in high-growth biotech companies.
aescap.comAmsterdam, Netherlands
PE firm focusing on seed and early stage companies based out of Belgium
kbcpe.beBrussels, Belgium
Early and mid-stage life science focused VC firm investing in the US and Europe
adventls.comLondon, United Kingdom
Premium access

Investor details for Biocartis

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Biocartis

31 people are tracked at Biocartis (9 in leadership, 4 in board & advisors, 18 in team).

NameRoleGroup
Anthony Green
Executive Vice President, Corporate & Business DevelopmentLeadership
Randy Polonsky
Chief Financial OfficerLeadership
Valentina Petrinec
Associate Director Strategic Accounts - ExportLeadership
Susy Spruyt
Chief People OfficerLeadership
Ann Claessens
Senior Human Resources Business Partner - L&d LeadLeadership
Roger Moody
CEOLeadership
Raf Pasmans
Business Director ExportLeadership
Chris van Haag
Senior Director Global Strategic PartnershipsLeadership
Paola Valente
Global Head Of Product Management And Product Management Lead OperationsLeadership
Ann-Christine Sundell
DirectorBoard & advisors
Luc Gijsens
DirectorBoard & advisors
Christian Reinaudo
Lead Independent DirectorBoard & advisors
Herman Verrelst
ChairmanBoard & advisors
Stefanie van Den Bosch
Legal ExpertTeam
Evelien Rondelez
Design And Development Support ManagerTeam
Sarah Saunders
Senior Product Specialist UK And IrelandTeam
Peter Mousa
Export Business ManagerTeam
Tiruneh Hailemariam
Clinical And Medical Affairs LeadTeam
Clifford Lynch
Senior Sourcing ManagerTeam
Julie Giraudeau
Key Account ManagerTeam

11 more people are available in the full profile.

Premium access

Complete people profiles for Biocartis

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Biocartis

Biocartis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Pronota.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Diagnostics for heart failure, pre-eclampsia, and sepsis are provided.
pronota.comGhent, Belgium2004Sep 2014••••
Premium access

Complete acquisition details for Biocartis

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Biocartis

5 dated milestones of Biocartis across 15 years, from founding to its latest funding, stage changes and deals.

  1. Founded Biocartis is founded.
  2. Funding First funding round of $14.9M.
  3. Acquisition Acquires Pronota.
  4. IPO Lists on the stock exchange (IPO).
  5. Funding Latest funding round, Post-IPO,.

Web traffic of Biocartis

The website of Biocartis (biocartis.com) receives about 10.5K visits a month and ranks #2,065,137 among all websites worldwide, #2,814 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    10.5K

    ▲ 9.3% vs previous month

  • Unique visitors
    3.9K

    per month

  • Global rank
    #2,065,137

    among all websites

  • Category rank
    #2,814

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Biocartis. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
flandersbio.be
flandersbio.be
100%
–
abionic.com
90%
View details
hartmann.info
52%
227.4K#190,702View details
mydiabby.com
50%
66.7K#376,957View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Biocartis

Premium access

Complete news archive for Biocartis

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Biocartis

Biocartis was founded in 2007 and raised its 1st funding round 2 years after it was founded.

Biocartis is headquartered in Mechelen, Belgium. It is registered at Mechelen, Antwerp, Belgium.

Biocartis is a funded company, having raised a total of $305.3M across 18 funding rounds to date. The company's 1st funding round was a Grant of $272.41K, raised on Oct 2009.

Biocartis was founded in 2007 in Mechelen, Belgium, within the molecular diagnostics sector. Proprietary micro-technology platforms are utilized for integrated molecular and immunodiagnostics. Multiplexed detection, quantification, and amplification of bio-analytes such as proteins, nucleic acids, and small molecules are enabled. Analysis of biomolecules linked to disease risk factors, early detection, staging, treatment selection, and monitoring is supported across various applications.

Biocartis offers Idylla Platform, Oncology Tests, and Research Assays.

Biocartis has made 1 acquisition, including Pronota.

Biocartis has 19 investors. Key investors include Philips, Johnson & Johnson, KBC Bank & Verzekering, Debiopharm, and PMV.

Biocartis operates through Biocartis Nv.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available